Cancer in Parkinson’s Disease, a Review of Literature

1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427-42.10.1212/WNL.17.5.427 Search in Google Scholar

2. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: record linkage studies. J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):215-21..10.1136/jnnp.2009.17546319726405 Search in Google Scholar

3. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson’s disease. Ann Neurol. 1985 May;17(5):505-9.10.1002/ana.4101705144004173 Search in Google Scholar

4. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH. Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. Int J Cancer. 2012 Oct 15;131(8):1904-11.10.1002/ijc.27443363676922278152 Search in Google Scholar

5. Skibba JL, Pinckley J, Gilbert EF, Johnson RO. Multiple primary melanoma following administration of levodopa. Arch Pathol. 1972 Jun;93(6):556-61. Search in Google Scholar

6. Sandyk R. Accelerated growth of malignant melanoma by levodopa in Parkinson’s disease and role of the pineal gland. Int J Neurosci. 1992 Mar;63(1-2):137-40.10.3109/002074592089866631342025 Search in Google Scholar

7. Kincannon J, Boutzale C. The physiology of pigmented nevi. Pediatrics. 1999 Oct;104(4 Pt 2):1042-5.10.1542/peds.104.S5.1042 Search in Google Scholar

8. Gurney H, Coates A, Kefford R. The Use of L-Dopa and Carbidopa in Metastatic Malignant-Melanoma. Journal of Investigative Dermatology. 1991 Jan;96(1):85-7.10.1111/1523-1747.ep125158961987300 Search in Google Scholar

9. Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, et al. Nonfatal cancer preceding Parkinson’s disease: A case-control study. Epidemiology. 2002 Mar;13(2):157-64.10.1097/00001648-200203000-0001011880756 Search in Google Scholar

10. Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology. 2006 Sep;17(5):582-7.10.1097/01.ede.0000229445.90471.5e16837822 Search in Google Scholar

11. Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK, et al. Risk of cancer after the diagnosis of Parkinson’s disease: A historical cohort study. Movement Disord. 2005 Jun;20(6):719-25.10.1002/mds.2040115704188 Search in Google Scholar

12. Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S. Treatment with levodopa and risk for malignant melanoma. Movement Disord. 2007 Jul 15;22(9):1252-7.10.1002/mds.2139717534943 Search in Google Scholar

13. Devine MJ, Plun-Favreau H, Wood NW. Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer. 2011 Nov;11(11):812-+.10.1038/nrc315022020207 Search in Google Scholar

14. Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease. J Neural Transm. 2011 Aug;118(8):1199-207.10.1007/s00702-011-0580-221298300 Search in Google Scholar

15. Pan TH, Li XQ, Jankovic J. The association between Parkinson’s disease and melanoma. International Journal of Cancer. 2011 May 1;128(10):2251-60.10.1002/ijc.2591221207412 Search in Google Scholar

16. Wick MM, Byers L, Frei E, 3rd. L-dopa: selective toxicity for melanoma cells in vitro. Science. 1977 Jul 29;197(4302):468-9.10.1126/science.877570877570 Search in Google Scholar

17. Gurney H, Coates A, Kefford R. The Use of L-Dopa and Carbidopa in Metastatic Malignant-Melanoma. Journal of Investigative Dermatology. 1991 Jan;96(1):85-7.10.1111/1523-1747.ep125158961987300 Search in Google Scholar

18. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat Disord. 2003 Aug;9(6):321-7.10.1016/S1353-8020(03)00040-312853231 Search in Google Scholar

19. Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease. Mov Disord. 2010 Sep 15;25(12):1801-8.10.1002/mds.2300620669311 Search in Google Scholar

20. Inzelberg R, Flash S, Friedman E, Azizi E. Cutaneous malignant melanoma and Parkinson disease: Common pathways? Ann Neurol. 2016 Dec;80(6):811-20.10.1002/ana.2480227761938 Search in Google Scholar

21. Rigel DS, Patel Z, Bolognia J, Eichler C, Ellis DL, Friedman RJ. Evaluation of Parkinson’s disease (PD) prevalence in patients with malignant melanoma (MM). Movement Disord. 2006;21:S58-S. Search in Google Scholar

22. Baade D, Fritschi L, Freedman DM. Mortality due to amyotrophic lateral sclerosis and Parkinson’s disease among melanoma patients. Neuroepidemiology. 2007;28(1):16-20.10.1159/00009785117164565 Search in Google Scholar

23. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson’s disease. British Journal of Cancer. 2005 Jan 17;92(1):201-5.10.1038/sj.bjc.6602279236175315583688 Search in Google Scholar

24. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Cancer risk in association with Parkinson disease: A population-based study. Parkinsonism Relat D. 2010 Mar;16(3):186-90.10.1016/j.parkreldis.2009.11.00519945903 Search in Google Scholar

25. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiology Biomarkers & Prevention. 2007 Jun;16(6):1260-5.10.1158/1055-9965.EPI-07-003817548694 Search in Google Scholar

26. Sun LM, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH. Analysis of Parkinson’s Disease and Subsequent Cancer Risk in Taiwan: A Nationwide Population-Based Cohort Study. Neuroepidemiology. 2011;37(2):114-9.10.1159/00033148921986194 Search in Google Scholar

27. Lai SW, Liao KF, Lin CH, Tsai PY, Sung FC. Parkinson’s disease and lung cancer: A population-based case-control study in Taiwan. Geriatr Gerontol Int. 2013 Jan;13(1):238-40.10.1111/j.1447-0594.2012.00919.x23286570 Search in Google Scholar

28. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Neurology. 2007 Mar 20;68(12):A258-A. Search in Google Scholar

29. Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in Parkinson’s disease. Front Neuroendocrin. 2009 Jul;30(2):142-57.10.1016/j.yfrne.2009.04.01419410597 Search in Google Scholar

30. Giovannelli P, Di Donato M, Giraldi T, Migliaccio A, Castoria G, Auricchio F. Targeting rapid action of sex-steroid receptors in breast and prostate cancers. Front Biosci-Landmrk. 2011 Jun 1;16:2224-32.10.2741/384921622172 Search in Google Scholar

31. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol. 2000 Jun;247(6):429-34.10.1007/s00415007017110929271 Search in Google Scholar

32. Qiu LX, Yuan H, Yu KD, Mao C, Chen B, Zhan P, et al. Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46,281 subjects. Breast Cancer Res Treat. 2010 Jun;121(3):703-8.10.1007/s10549-009-0636-219936916 Search in Google Scholar

33. Cai QL, Wang Z, Zhang W, Guo XM, Shang ZQ, Jiang N, et al. Association between glutathione S-transferases M1 and T1 gene polymorphisms and prostate cancer risk: a systematic review and meta-analysis. Tumor Biol. 2014 Jan;35(1):247-56.10.1007/s13277-013-1030-623888321 Search in Google Scholar

34. Wang TF, Wang B. Association between Glutathione S-transferase M1/Glutathione S-transferase T1 polymorphisms and Parkinson’s disease: A meta-analysis. Journal of the Neurological Sciences. 2014 Mar 15;338(1-2):65-70.10.1016/j.jns.2013.12.01824382428 Search in Google Scholar

35. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol. 2000 Jun;247(6):429-34.10.1007/s00415007017110929271 Search in Google Scholar

36. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson’s disease. British Journal of Cancer. 2005 Jan 17;92(1):201-5.10.1038/sj.bjc.6602279236175315583688 Search in Google Scholar

37. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH. Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. International Journal of Cancer. 2012 Oct 15;131(8):1904-11.10.1002/ijc.27443363676922278152 Search in Google Scholar

38. Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared Predispositions of Parkinsonism and Cancer A Population-Based Pedigree-Linked Study. Arch Neurol-Chicago. 2012 Dec;69(12):1572-7.10.1001/archneurol.2012.226122945795 Search in Google Scholar

39. Kravitz E, Laitman Y, Hassin-Baer S, Inzelberg R, Friedman E. Parkinson’s disease genes do not segregate with breast cancer genes’ loci. Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1464-72.10.1158/1055-9965.EPI-13-047223765085 Search in Google Scholar

40. Routh JC, Crimmins CR, Leibovich BC, Elliott DS. Impact of Parkinson’s disease on continence after radical prostatectomy. Urology. 2006 Sep;68(3):575-7.10.1016/j.urology.2006.03.02516979722 Search in Google Scholar

41. Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol. 2015 Oct 7;21(37):10609-20.10.3748/wjg.v21.i37.10609458808326457021 Search in Google Scholar

42. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014 Oct;12(10):661-72.10.1038/nrmicro334425198138 Search in Google Scholar

43. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord. 2004 Jan;19(1):49-53.10.1002/mds.1064814743360 Search in Google Scholar

44. Ong EL, Goldacre R, Goldacre M. Differential risks of cancer types in people with Parkinson’s disease: a national record-linkage study. Eur J Cancer. 2014 Sep;50(14):2456-62.10.1016/j.ejca.2014.06.01825065294 Search in Google Scholar

45. Wirdefeldt K, Weibull CE, Chen H, Kamel F, Lundholm C, Fang F, et al. Parkinson’s disease and cancer: A register-based family study. Am J Epidemiol. 2014 Jan 1;179(1):85-94.10.1093/aje/kwt232386471424142916 Search in Google Scholar

46. Lin PY, Chang SN, Hsiao TH, Huang BT, Lin CH, Yang PC. Association Between Parkinson Disease and Risk of Cancer in Taiwan. Jama Oncol. 2015 Aug;1(5):633-40.10.1001/jamaoncol.2015.175226181771 Search in Google Scholar

47. Xie X, Luo XG, Xie ML. Association between Parkinson’s disease and risk of colorectal cancer. Parkinsonism Relat D. 2017 Feb;35:42-7.10.1016/j.parkreldis.2016.11.01127913126 Search in Google Scholar

48. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett. 2006 Mar 20;396(1):67-72.10.1016/j.neulet.2005.11.01216330147 Search in Google Scholar

49. Schernhammer E, Chen HL, Ritz B. Circulating melatonin levels: Possible link between Parkinson’s disease and cancer risk? Cancer Causes & Control. 2006 May;17(4):577-82.10.1007/s10552-005-9002-916596313 Search in Google Scholar

50. Sarkar C, Chakroborty D, Dasgupta PS, Basu S. Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia. International Journal of Cancer. 2015 Aug 1;137(3):744-9.10.1002/ijc.29414443788425556636 Search in Google Scholar

51. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Jr., Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord. 2006 Apr;12(3):185-9.10.1016/j.parkreldis.2005.09.00416364673 Search in Google Scholar

52. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is Diabetes Mellitus an Independent Risk Factor for Colon Cancer and Rectal Cancer? Am J Gastroenterol. 2011 Nov;106(11):1911-21.10.1038/ajg.2011.301374145321912438 Search in Google Scholar

53. Powers KM, Smith-Weller T, Franklin GA, Longstreth WT, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat D. 2006;12(3):185-9.10.1016/j.parkreldis.2005.09.004 Search in Google Scholar

54. Ruiz-Martínez J, de la Riva P, Rodríguez-Oroz MC, Mondragón Rezola E, Bergareche A, Gorostidi A, et al. Prevalence of cancer in Parkinson’s disease related to R1441G and G2019S mutations in LRRK2. Mov Disord. 2014 May;29(6):750-5.10.1002/mds.2577824357540 Search in Google Scholar

55. Paisan-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology. 2010 Nov 2;75(18):1653-5.10.1212/WNL.0b013e3181fb446621041788 Search in Google Scholar

56. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5956-61.10.1073/pnas.093126210015630812719539 Search in Google Scholar

57. Waro BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson’s disease. Brain Behav. 2018 Jan;8(1).10.1002/brb3.858585362729568677 Search in Google Scholar

58. West AB, Dawson VL, Dawson TM. To die or grow: Parkinson’s disease and cancer. Trends Neurosci. 2005 Jul;28(7):348-52.10.1016/j.tins.2005.05.00215913799 Search in Google Scholar

59. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007 Oct 9;69(15):1542-50.10.1212/01.wnl.0000277638.63767.b817699801 Search in Google Scholar

60. Zanetti R, Loria D, Rosso S. Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res. 2006 Jun;16(3):201-6.10.1097/01.cmr.0000215043.61306.d716718266 Search in Google Scholar

61. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 2009 Oct 20;73(16):1286-91.10.1212/WNL.0b013e3181bd13a1276441719841380 Search in Google Scholar

62. Bajaj A, Driver JA, Schernhammer ES. Parkinson’s disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010 May;21(5):697-707.10.1007/s10552-009-9497-620054708 Search in Google Scholar

63. Greenamyre JT, Hastings TG. Biomedicine. Parkinson’s--divergent causes, convergent mechanisms. Science. 2004 May 21;304(5674):1120-2.10.1126/science.109896615155938 Search in Google Scholar

64. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239-67.10.1146/annurev.pharmtox.44.101802.12185114744246 Search in Google Scholar

65. Kim RH, Mak TW. Tumours and tremors: how PTEN regulation underlies both. British Journal of Cancer. 2006 Mar 13;94(5):620-4.10.1038/sj.bjc.6602994236120416495927 Search in Google Scholar

66. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Navajas RFC. Smoking and Parkinson’s disease: Systematic review of prospective studies. Movement Disord. 2004 Jun;19(6):614-21.10.1002/mds.2002915197698 Search in Google Scholar